Skip to main navigation ABOUT R&D PIPELINE INVESTORS & MEDIA CAREERS Investors & Media Overview News Events & Presentations Annual Reports Stock Information SEC Filings Corporate Governance Investor Resources NOVEMBER 9, 2021 AT 6:30 AM EST NGM Bio to Participate in Upcoming Investor Conferences PDF Version SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming 2021 virtual investor conferences: Stifel 2021 Virtual Healthcare Conference Monday, November 15, 2021, 2:40pm ET Jefferies London Healthcare Conference Thursday-Friday, November 18-19, 2021; presentation available on-demand beginning November 18, 2021, 3:00am ET 33rd Annual Piper Sandler Healthcare Conference Tuesday-Thursday, November 30-December 2, 2021; presentation available on-demand beginning November 22, 2021, 10:00am ET Evercore ISI Healthcare Conference Wednesday, December 1, 2021, 1:25pm ET Live webcasts of presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of each presentation will be archived on NGM’s site for at least 30 days following the event. About NGM Biopharmaceuticals, Inc. NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying retinal diseases, cancer and liver and metabolic diseases. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. All of our therapeutics have been generated by our in-house discovery engine; today, we have seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutics areas. Visit us at www.ngmbio.com for more information. Investor Contact: Brian Schoelkopf ir@ngmbio.com Media Contact: Liz Melone media@ngmbio.com CONTACT INFORMATION INVESTOR RELATIONS: ir@ngmbio.com MEDIA RELATIONS: media@ngmbio.com TOOLKIT Email Alerts RSS Print Email Page Search © 2021 NGM Biopharmaceuticals. All Rights Reserved. Contact. Privacy Policy. Terms of Use.